IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia

IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia

Abstract Background Surface antigens of potential clinical significance remain under-characterized in AML. The European Leukemia Network classifies normal karyotype AML (NK-AML) mutated for NPM1 (NPM1c) as a distinct entity associated with favorable outcomes if not associated with FLT3-ITD mutation....

Full description

Saved in:
Bibliographic Details
Main Authors: Arnaud Métois, Marie-Eve Bordeleau, Louis Theret, Azadeh Hajmirza, Ossama Moujaber, Jean-François Spinella, Jalila Chagraoui, Nadine Mayotte, Isabel Boivin, Éric Audemard, Léo Aubert, Véronique Lisi, Banafsheh Khakipoor, Azer Farah, Éric Bonneil, Alma Robert, Julie Lippens, Anna Moraitis, François Béliveau, Albert Feghaly, Geneviève Boucher, Richard Marcotte, Patrick Gendron, Pierre Thibault, Sébastien Lemieux, Guillaume Richard-Carpentier, Vincent-Philippe Lavallée, Josée Hébert, Philippe P. Roux, Guy Sauvageau
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Biomarker Research
Subjects:
IL1RAP
Acute myeloid leukemia
Surfaceome
Immunotherapy
Cancer
Single cell
Online Access:https://doi.org/10.1186/s40364-025-00769-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40364-025-00769-z

Similar Items